Trials / Terminated
TerminatedNCT04435782
A Study of Selexipag Assessing Right Ventricular Remodeling in Pulmonary Arterial Hypertension by Cardiac Magnetic Resonance Imaging
A Prospective, Multicenter, Single-Arm, Open-Label, Phase 4 Study of the Effects of Selexipag on Right Ventricular Remodeling in Pulmonary Arterial Hypertension Assessed by Cardiac Magnetic Resonance Imaging
- Status
- Terminated
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 9 (actual)
- Sponsor
- Actelion · Industry
- Sex
- All
- Age
- 18 Years – 64 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to assess the effects of selexipag on right ventricular (RV) function in participants with Pulmonary arterial hypertension (PAH).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | JNJ-67896049 | Participants will receive tablets at a starting dose of 200 mcg on Day 1. Dose will be up-titrated from Day 1 to the end of Week 12 (Day 84) to determine individual maintenance dose (IMD). Then, participants will receive JNJ-67896049 tablets at their IMD from Week 13 to Week 52. |
Timeline
- Start date
- 2021-07-07
- Primary completion
- 2023-07-28
- Completion
- 2023-07-28
- First posted
- 2020-06-17
- Last updated
- 2025-03-30
- Results posted
- 2024-08-20
Locations
35 sites across 15 countries: United States, Argentina, Brazil, France, Germany, Hong Kong, Israel, Malaysia, Netherlands, Russia, Saudi Arabia, Singapore, South Korea, United Arab Emirates, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04435782. Inclusion in this directory is not an endorsement.